Skip to content

688185.SH

CanSino Biologics, Inc.

SSE · Healthcare · Biotechnology · CN

CNY 78.57
+8.97%
Ask drillr

Year over year

Reported trailing growth

Revenue
+29.0%
EBITDA
—
EBIT
+102.8%
EPS
+100.2%
Free cash flow
+63.4%
Operating cash flow
+151.8%

Forward estimates

Based on analyst estimates

Revenue
-56.5%
EBITDA
-20.2%
EPS
—

Three-year CAGR

Revenue
+1.1%
EBITDA
+212.3%
EBIT
+106.4%
Net income
+107.4%
EPS
+107.2%
Free cash flow
+75.5%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026